Free press releases distribution network?

Agency / Source: AnaSpec, Inc.

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



AnaSpec Launches the EnzoLyte™ 520 Renin Assay Kit with Ultra-high Sensitivity - The past decade has witnessed the development of a number of synthetic renin inhibitors1-3
AnaSpec Launches the EnzoLyte™ 520 Renin Assay Kit with Ultra-high Sensitivity

 

PRZOOM - /newswire/ - San Jose, CA, United States, 2007/01/08 - The past decade has witnessed the development of a number of synthetic renin inhibitors1-3.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

However, increasing demand for accelerated drug discovery and automated inhibitor screening has generated a need for a continuous, homogeneous assay with even greater sensitivity. With the introduction of the ultra-sensitve EnzoLyte™ 520 Renin Assay Kit, AnaSpec now offers a renin assay kit that is 40x more sensitive than comparable kits currently in the market.

Renin, a highly specific aspartyl protease, cleaves angiotensinogen, to yield angiotensin I, which is further converted into angiotensin II by ACE (Angiotensin Converting Enzyme). Angiotensin II constricts blood vessels, leading to increased blood pressure. Angiotensin II also increases the secretion of ADH and aldosterone, and stimulates the hypothalamus to activate the thirst reflex. Since an overactive renin-angiotensin system leads to hypertension, renin is an attractive target for the treatment of this disease.

While existing renin assay kits offer sub-nanomolar potency and selectivity, AnaSpec’s EnzoLyte™ 520 Renin Assay Kit offers picomolar sensitivity – the highest sensitivity available for commercial renin assay kits.

AnaSpec also offers a shorter emission wavelength kit, EnzoLyte™ 390 Renin Assay Kit -a cost-effective option that offers greater sensitivity than EDANS/DABCYL-based renin assay kits.

EnzoLyte™ 520 Renin Assay Kit
EnzoLyte™ 390 Renin Assay Kit

EnzoLyte™ 520 Renin Assay Kit
FRET pair: 5-FAM/QXLTM520
Ex/Em (nm): 490/520
Min. Detectable Renin Conc. (pM): 2.5
Interference from Autofluorescence: Minimal
Sensitivity: Ultra-sensitive

EnzoLyte™ 390Renin Assay Kit
FRET pair: Mc-Ala/Dnp
Ex/Em (nm): 330/390
Min. Detectable Renin Conc. (pM): 25
Interference from Autofluorescence: High
Sensitivity: Good

Company B
FRET pair: EDANS/DABCYL
Ex/Em (nm): 335/495
Min. Detectable Renin Conc. (pM):100
Interference from Autofluorescence:High
Sensitivity: Minimal

For more information, visit our website.

AnaSpec, Inc., located in San Jose, CA, is a leading provider of integrated proteomics solutions to pharmaceutical, biotech, and academic research institutions throughout the world. With a vision for innovation through synergy, AnaSpec focuses on three core technologies: peptides, detection reagents, and combinatorial chemistry.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: AnaSpec, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


AnaSpec Launches the EnzoLyte™ 520 Renin Assay Kit with Ultra-high Sensitivity

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Debra Thai 
408 452-5055 marketing[.]anaspec.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any AnaSpec, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From AnaSpec, Inc. / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine
Somatuline® Autogel® 120 Mg Receives Japanese Approval for A New Indication for the Treatment of Gastro-entero-pancreatic Neuroendocrine Tumors
OTC Topical Drugs Market Size will Grow Profitably in the Near Future 2017-2025 Finds PMR
Bioinformatics Market Size to Expand at 20.4% CAGR through 2020 Reports Persistence Market Research
Australia Nitric Acid Market Expected to Reach at Value of $1.3B by 2024 End Says PMR

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  NAKIVO, Inc.

Visit  MagLar, Inc.

Visit  JobsWare.com







 
  ©2017 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today